Oesophageal Adenocarcinoma Clinical Trials

3 recruiting

Frequently Asked Questions

Common questions about Oesophageal Adenocarcinoma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 111 of 11 trials

Recruiting
Phase 1Phase 2

Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)

Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC160 enrolled43 locationsNCT06469944
Recruiting
Phase 1Phase 2

Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)

Esophageal CancerEsophageal NeoplasmsGastroesophageal Junction+1 more
Merck Sharp & Dohme LLC210 enrolled43 locationsNCT06445972
Recruiting
Phase 2

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

Gastroesophageal Adenocarcinoma
AstraZeneca100 enrolled70 locationsNCT07069712
Recruiting
Phase 2

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

Esophageal AdenocarcinomaGastric AdenocarcinomaPancreas Adenocarcinoma+6 more
Yale University54 enrolled1 locationNCT07282912
Recruiting
Phase 2

Zanidatamab in Combination With Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesophageal Adenocarcinoma (GEA) Patients

MetastasesHER2 + Gastric CancerFirst Line Therapy+2 more
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest80 enrolled20 locationsNCT07176312
Recruiting
Not Applicable

Will a Pre-therapy Exercise Intervention Improve the Outcomes of Patients With Advanced Oesophageal Cancer?

ExerciseTumor MicroenvironmentT Cells+1 more
University of Surrey50 enrolled1 locationNCT07375420
Recruiting
Phase 1Phase 2

A First-in-Human Study Using BDC-4182 as a Single Agent in Advanced Gastric and Gastroesophageal Cancer

Gastroesophageal AdenocarcinomaGastric Cancer Adenocarcinoma Metastatic
Bolt Biotherapeutics, Inc.122 enrolled16 locationsNCT06921837
Recruiting
Phase 1

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Muscle-Invasive Bladder CarcinomaGastroesophageal Adenocarcinoma
Washington University School of Medicine32 enrolled1 locationNCT06529822
Recruiting
Phase 2

Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer

Metastatic Colorectal CancerMetastatic Gastroesophageal AdenocarcinomaDPD Deficiency
UNICANCER73 enrolled21 locationsNCT06245356
Recruiting
Phase 2

Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy

Tumor MicroenvironmentOesophageal Adenocarcinoma
Amsterdam UMC, location VUmc14 enrolled2 locationsNCT06687876
Recruiting

Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery

Gastric AdenocarcinomaOesophageal Adenocarcinoma
Imperial College London100 enrolled1 locationNCT06289374